



I hereby certify that this correspondence is being deposited with the United States Postal Service in an envelope addressed to:

Mail Stop Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

On 10-12-06

TOWNSEND and TOWNSEND and CREW LLP

By: Linda Sheffer

PATENT  
Attorney Docket No.: 015280-290110US  
Client Ref. No.: E-171-1996/0-US-03  
Customer No.: 45115

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re application of:

KLIMPEL *et al.*

Application No.: 09/853,530

Filed: May 9, 2001

For: TARGETING ANTIGENS TO THE  
MHC CLASS I PROCESSING  
PATHWAY WITH AN ANTHRAX  
TOXIN FUSION PROTEIN

Confirmation No. 7146

Examiner: Schwadron, Ronald B.

Art Unit: 1644

COMMUNICATION UNDER

37 C.F.R. §§ 1.821-1.825

AND

AMENDMENT

Mail Stop Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

In response to the Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures, 37 C.F.R. §§ 1.821-1.825, that accompanied the Office Communication mailed August 17, 2006, Applicants submit herewith the required paper copy and computer readable copy of the Sequence Listing. Please amend the specification as follows.

Appl. No. 09/853,530

Amdt. dated September 25, 2006

Reply to Office Communication of August 17, 2006

PATENT

**Amendments to the Specification** begin on page 3 of this paper.

**Remarks** begin on page 6 of this paper: